WINNIPEG, MANITOBA--(MARKET WIRE)--Jul 16, 2007 -- DiaMedica Inc. (CDNX:DMA.V - News), a clinical stage biotechnology company developing novel treatments for various stages of type 2 diabetes, is pleased to announce that the final patient has completed the treatment period in its phase II study evaluating DM-71 in the treatment of type 2 diabetes.